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Optimizing menopausal hormone therapy (MHT) requires 
an awareness of the benefits and risks associated with the 
available treatments. This narrative review, which is based on the 
proceedings of an Advisory Board meeting and supplemented 
by relevant articles identified in literature searches, examines the 
role of progestogens in MHT, with the aim of providing practical 
recommendations for prescribing physicians. Progestogens are 
an essential component of MHT in menopausal women with a 
uterus to prevent endometrial hyperplasia and reduce the risk of 
cancer associated with using unopposed estrogen. Progestogens 
include natural progesterone, dydrogesterone (a stereoisomer of 
progesterone), and a range of synthetic compounds. Structural 
differences and varying affinities for other steroid receptors 
(androgen, glucocorticoid, and mineralocorticoid) confer a 
unique biological and clinical profile to each progestogen 
that must be considered during treatment selection. MHT, 
including the progestogen component, should be tailored to 
each woman, starting with an estrogen and a progestogen 
that has the safest profile with respect to breast cancer and 
cardiovascular effects, while addressing patient-specific needs, 
risk factors, and treatment goals. Micronized progesterone and 
dydrogesterone appear to be the safest options, with lower 
associated cardiovascular, thromboembolic, and breast cancer 
risks compared with other progestogens, and are the first-choice 
options for use in ‘special situations,’ such as in women with 
high-density breast tissue, diabetes, obesity, smoking, and risk 
factors for venous thromboembolism, among others. 
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Declining estrogen levels at menopause produce a wide range 
of signs and symptoms, including vasomotor symptoms, sleep 
disturbances, changes in mood and energy levels, urogenital 
atrophy, sexual dysfunction, and decreased bone density.1,2 
If severe, menopausal symptoms can affect a woman’s daily 
functioning and impair her quality of life. Moreover, the timing 
of menopause coincides with the emergence of age-related 
chronic diseases.3,4
Menopausal hormone therapy (MHT) has been shown to have a 
favorable risk–benefit ratio in women without contraindications 
who initiate treatment between the ages of 50–59 years 
or within 10 years of menopause onset.5–11 In this defined 
population, MHT effectively relieves vasomotor and urogenital 
symptoms, can prevent bone loss and fracture,6–11 and may 
protect against all-cause mortality and cardiac events.12,13
MHT encompasses several drug classes, including estrogens, 
progestogens, estrogen plus progestogen combinations, 
synthetic steroids (e.g. tibolone), and selective estrogen 
receptor modulators (e.g. raloxifene, bazedoxifene, 
ospemifene).5,11 The wide range of formulations and delivery 
systems allows for individualized treatment based on a 
woman’s symptoms, risk factors, and treatment goals. However, 
because the risks and benefits of MHT differ depending on the 
type, dose, formulation, route of administration, duration of 
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use, and timing of initiation,10,11 prescribing physicians must be 
well informed in order to optimize treatment.14
Persistent negative attitudes towards MHT following publication 
of the Women’s Health Initiative studies in the early 2000s led 
to a virtual abandonment of MHT use and of medical education 
about menopause and MHT.15,16 Many physicians today are 
not comfortable providing care to menopausal women, 
resulting in unnecessary suffering and wasted opportunities 
for better health outcomes.16 As a step towards resolving the 
knowledge gap, this narrative review examines the use of 
MHT in menopausal women, with an emphasis on the role of 
progestogens in MHT. The expertise and clinical experience 
of the authors is supported by relevant literature (e.g. clinical 
guidelines) with the aim of providing practical recommendations 
for prescribing physicians, including in special situations such as 
obesity, diabetes, and others, where uncertainty may be greater.
Content-development methods
This review was developed primarily from the proceedings of an 
Advisory Board meeting attended by the authors held in Lisbon 
in October 2019, organized by Mylan Pharmaceuticals. The aims 
of the meeting were to differentiate between progestogens 
and their roles in menopause management and establish 
consensus recommendations to treat menopausal women in 
everyday practice. Published reviews of the differential actions 
of progestogens used in MHT formed the basis of the discussion 
and generated the topics to be covered in this review. Review 
articles were supplemented by clinical practice guidelines and 
other relevant materials identified through PubMed searches 
or known to the authors. Some content reflects the clinical 
experience and expert opinion of the authors.
Pharmacology of progestogens
Progestogens are a class of steroid hormones that bind to and 
activate the progesterone receptor. In women, progesterone 
receptors are found in the uterus, breast, ovary, brain, bone, 
and other tissues. Endogenous progesterone is an essential 
regulator of female reproductive function and has an integral 
role in the normal physiology of the cardiovascular system, 
bone, and central nervous system.17
Progestogens is a collective term that encompasses 
natural progesterone, dydrogesterone (a stereoisomer of 
progesterone), and a range of synthetic compounds designed 
to mimic the action of endogenous progesterone.18 Although 
progestogens vary widely in their molecular structures, they 
all derive from progesterone, testosterone, or spironolactone 
(Table 1).19,20 Progestogens commonly used for MHT in clinical 
practice in Europe include progesterone, dydrogesterone, 
medroxyprogesterone acetate, norethisterone acetate 
(norethindrone), nomegestrol acetate, (levo)norgestrel, and 
dienogest.
Table 1. Classification of progestogens.19,20
Natural Progesterone
Retroprogesterone Dydrogesterone
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Apart from binding to progesterone receptors, progestogens 
may interact to varying degrees with other steroid receptors 
(androgen, glucocorticoid, and mineralocorticoid receptors). 
The relative binding affinities and biological activities of 
commonly prescribed progestogens at steroid receptors are 
shown in Supplementary Table 1 (available at: https://www.
drugsincontext.com/wp-content/uploads/2020/11/dic.2020-
10-1-Suppl.pdf).18,21,22 As differences in the chemical structures, 
metabolism, pharmacokinetics, and receptor affinities of 
progestogens confer individual biological and clinical profiles, 
progestogens are considered to lack a class effect.18,19
The specific biological profile of a progestogen can affect its 
tolerability, although it can also be used to achieve certain 
clinical effects or mitigate underlying risk factors.21 As 
examples, androgenic progestogens may antagonize estrogen-
induced changes in the hepatic synthesis of lipoproteins 
(high-density lipoprotein (HDL), very-low-density lipoprotein 
(VLDL), triglycerides), coagulation and fibrinolysis factors, 
angiotensinogen, and hormone-binding globulins.21 Progestogens 
with glucocorticoid activity may increase pro-coagulatory activity 
in vessel walls.21 Androgenic progestogens may attenuate 
estrogen-induced hypercoagulability and the risk of venous 
thromboembolism (VTE).21 Progestogens with antiandrogenic 
effects may be useful to manage androgenic cutaneous 
disorders.21 Progestogens with antimineralocorticoid properties 
may induce a transient reduction in aldosterone-induced water 
retention in predisposed patients,21 combating fluid overload and 
lowering blood pressure.23
Selecting a progestogen for MHT requires an understanding 
of the differential risks and benefits associated with their 
metabolic profiles. Although direct clinical comparisons of 
progestogens are lacking, evidence for the biological and 
clinical effects of individual progestogens on the endometrium, 
breast, cardiovascular system, bone, and brain has been 
previously reviewed.19–24
Progestogens in menopause 
management
Role of progestogens
Estrogen is the main component of MHT that relieves the 
vasomotor and urogenital symptoms of menopause and 
protects against osteoporosis.6–11 Administered early in 
menopause, estrogen also attenuates the atherosclerotic 
process, thus protecting women from coronary heart disease, 
which may be particularly important in women with early 
menopause.12 Women with a uterus require a progestogen to 
prevent endometrial hyperplasia and the risk of endometrial 
cancer associated with the use of unopposed estrogen.19,24
Route of administration
Progestogens for use in MHT are available as single agents for 
concomitant use with estrogen or in fixed combinations with 
estradiol. Free (i.e. not fixed) combinations of estrogen and 
progestogen may facilitate treatment individualization in terms 
of dosage and formulation. Routes of administration for MHT 
include oral, vaginal, transdermal, and intrauterine.19,24
Progesterone for use in MHT is micronized to enhance its 
bioavailability. Progesterone is commonly administered orally, 
although it is also formulated for vaginal administration. Oral and 
vaginal (but not transdermal) micronized progesterone provide 
endometrial protection.25 Dydrogesterone is administered orally. 
Other progestogens for use in MHT are usually administered 
orally, although some are available as an intrauterine device (e.g. 
levonorgestrel intrauterine system) for use with estrogen or may 
be formulated with estrogen in a transdermal patch. Treatment 
selection must consider the benefits and disadvantages 
associated with each route of administration.
Contraindications
Contraindications for MHT include unexplained vaginal 
bleeding; a history of stroke, transient ischemic attack, 
myocardial infarction, pulmonary embolism, or VTE; breast 
or endometrial cancer; or active liver disease.6 Principal 
contraindications for progestogens are breast cancer and 
undiagnosed abnormal vaginal bleeding.
Adverse effects
The common adverse effects associated with progestogens 
in MHT are breakthrough bleeding and breast discomfort.26 
Other possible adverse effects include headache, nausea, 
somnolence, fatigue, weight gain, abdominal bloating, anxiety, 
irritability, depression, decreased libido, hirsutism and acne, 
back pain, and myalgia.26
Selecting a progestogen
As tolerability to progestogens varies considerably among 
women, treatment must be individualized. Treatment should 
begin with a progestogen that has the lowest risk profile 
regarding breast cancer and cardiovascular effects,26 while 
addressing patient-specific needs and risk factors. Numerous 
opinion leaders, guideline groups, and menopause societies 
recommend adding either micronized progesterone or 
dydrogesterone to estrogen therapy as the associated 
cardiovascular, thromboembolic, and breast cancer risks 
are lower with these molecules compared with other 
progestogens.5,6,8,9,11,26–31 Progesterone and its derivatives 
are less likely than androgenic progestogens to attenuate the 
beneficial effects of estrogens on lipoprotein metabolism,32 
which may be relevant for patients at higher risk for 
cardiovascular disease (CVD).
Progestogen dose
The recommended daily dose of progestogen varies by agent 
and is a reflection of its endometrial effectiveness as assessed in 
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studies using endometrial biopsies.33 The dose and duration of 
a progestogen also depend on the estrogen dose. As estrogen 
doses are currently much lower than those used previously, 
correspondingly lower doses of progestogen are required to 
balance the estrogenic effects. Progestogens for use in MHT 
are available in numerous formulations. Dosing details for each 
agent and formulation can be found in the associated Summary 
of Product Characteristics (Europe), Prescribing Information 
(United States), and/or national pharmaceutical compendiums.
When and how to treat patients
Prescribing MHT
The goal of managing women through menopause is twofold: 
to address the initial symptoms/complaints and to reduce 
the long-term postmenopausal adverse outcomes. MHT is 
part of an overall management strategy that includes lifestyle 
measures aimed at promoting good health such as smoking 
avoidance, healthy diet, regular physical activity, moderate 
alcohol consumption, and weight management.6,34
MHT is indicated in symptomatic women without 
contraindications, aged 50–59 or within 10 years of menopause 
onset, whose menopausal symptoms are interfering with their 
quality of life.6–11 General guidance is that women should be 
prescribed ‘an appropriate type, dose, formulation, route of 
administration, and duration of MHT’ to meet their treatment 
objectives.10,11 Guidelines recommend starting with the lowest 
effective dose and up-titrating as required based on clinical 
response.6 The fully effective dose will vary by woman according 
to her age, symptom type, symptom severity, body mass index, 
time since menopause, and endometrial thickness and may need 
to be adjusted at various times during the course of therapy.10,11
MHT regimen
An MHT regimen may be sequential or continuous combined, 
depending on the stage of menopause.5,6,24
In newly menopausal women, a sequential MHT regimen 
(daily estrogen with a progestogen for 12–14 days/cycle) is 
appropriate. Regular progestogen withdrawal bleedings 
(i.e. monthly menses) will occur. Spotting within the first few 
months after starting MHT is relatively common and should be 
explained to patients beforehand. If irregular bleeding occurs, 
a first step may be to enquire about treatment adherence 
(e.g. unused patches/tablets). An underlying fear of MHT can 
negatively affect compliance, which can be addressed through 
counseling and reassurance. Irregular bleeding can also 
occur due to concurrent antibiotic use or digestive problems. 
Importantly, early spotting, which is normal, differs from 
bleeding that develops after many years of MHT use, which 
must be investigated thoroughly.
Women who have been postmenopausal for at least a year or 
those with weak or absent withdrawal bleeds can be switched 
to a continuous (daily) combined estrogen/progestogen 
regimen. Changes to MHT dosages and a wider range of 
progestogens have shortened this timeframe from the  
2–3 postmenopausal years previously required. In patients 
who may wish to start MHT with continuous combined 
therapy, factors such as age and endometrial thickness must be 
considered. Bleeding-free MHT is possible in patients with an 
endometrial thickness less than 5 mm.35
In Europe, the preferred estrogen for MHT is estradiol and the 
preferred progestogen is usually micronized progesterone 
or dydrogesterone. The route of administration of estrogen 
can be selected according to patient preference. With regard 
to the progestogen component, only norethisterone acetate 
and norgestrel are formulated for both oral and transdermal 
administration. The usual approach is to begin with a low 
dose of estrogen and titrate gradually until symptoms are 
controlled. Patients with severe symptoms may need to start 
with a medium dose of estrogen. If symptoms persist after 
4-12 weeks, the dose can be increased to achieve an adequate 
effect. Over time, some patients may achieve sufficient 
symptom control to allow for dosage reduction.
How long to maintain MHT?
Although most women will have discontinued MHT by their 
late 50s or early 60s, age alone is not a reason to stop.8,10,11 
Other factors that may inform a decision to continue or not 
to continue MHT include symptom severity with/without 
medication, bone mass, and the presence of risk factors for 
breast cancer. Symptomatic women who wish to continue MHT 
should not be denied treatment if there are no contraindications 
or changes to their risk status, although consideration should be 
given to using MHT formulations with the lowest risk.8
Women receiving MHT should be monitored regularly as 
treatment goals and choice of therapy may change over time. 
At least annual assessments are recommended to evaluate the 
risk–benefit balance and the patient’s desire to continue with 
treatment.34 Assessments may need to be more frequent in 
patients with concerns or risk factors. Adjustments to the dose 
or route of administration or switching to a different product are 
strategies that can be used to maintain therapy in women who 
wish to continue MHT.
After a period of time, possibly 3–5 years,36 tapering from 
MHT may be considered. Gradual dosage reduction may limit 
symptom recurrence (e.g. hot flashes) in the short term.5,37 If 
symptoms return, up-titrating to the original dose is an option. 
For women who wish to stop MHT altogether, reducing the 
dose over 2–3 months is preferable to stopping abruptly.37 
For practical reasons, treatment discontinuation is best not 
attempted during summer.
The physician’s role in menopause 
management
In Europe, gynecologists have primary responsibility for 
prescribing MHT and managing menopausal women although, 
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in a few countries (e.g. United Kingdom, The Netherlands), 
the responsibility lies with general practitioners.38 Effective 
management of menopausal women receiving MHT involves 
three basic aspects of care delivery: knowledge (clinical skills), 
communication, and regular assessment (Table 2).
Initial consultation for MHT
All candidates for MHT must undergo a thorough assessment 
and be informed about the risks and benefits. A full menopause 
consult takes considerably longer than a standard consult and 
needs to be scheduled accordingly.
A detailed personal and family history is essential as many 
chronic conditions begin to emerge after menopause.3,4  
A menopause consult also provides the opportunity to 
counsel women about the benefits of any lifestyle changes 
(e.g. smoking, diet, exercise, alcohol intake) that may be 
required to correct or prevent risk factors.6 Enquiring about 
colon cancer at the time of a menopause consult can promote 
participation in screening programs and is strongly advised. 
Some epidemiological data support a protective effect of 
MHT on colon cancer,39,40 although this does not constitute an 
indication for initiation of MHT.
Menopausal symptoms affect the central nervous system, 
musculoskeletal system, and genitourinary tract (Table 3). 
Symptoms such as sleep disorders, memory, or concentration 
difficulties (‘brain fog’) are not always recognized as 
menopausal. Conversely, some women may present with 
symptoms that are part of the menopause constellation (e.g. 
depression, insomnia) but are in fact attributable to other 
causes. It is important to establish a clear association between 
symptoms and menopause before prescribing MHT.6
A risk evaluation to identify comorbidities is appropriate for 
all MHT candidates. The extent of the assessment will depend 
Table 2. Physician’s role in menopause management.
Knowledge Physicians must have sound knowledge of:
•	 Guideline recommendations for MHT
•	 Choice of estrogen and progestogen (e.g. specific benefits of certain combinations)
•	 Risk mitigation in women with risk factors
•	 Absolute and relative contraindications for estrogens/progestogens
Communication Physicians must be able to:
•	 Effectively communicate the benefits and risks of MHT to patients to facilitate 
informed choices
•	 Provide reassurance and support during MHT as necessary for individual patients
Monitoring Physicians must:
•	 Monitor women regularly to identify changes in risk factors and to confirm the need 
for continued or modified treatment
•	 Schedule a follow-up within a few months (e.g. 3 months) of first prescription of 
MHT36 that includes a review of tolerability and side effects, especially bleeding 
disorders
•	 At least annual follow-up consultations are suggested thereafter to review and 
adjust MHT according to the patient’s treatment goals36 
MHT, menopausal hormone therapy.
Table 3. Symptoms of menopause.1
Central nervous system Vasomotor symptoms (hot flushes, night sweats); mood disturbances (anxiety, 
depression); cognitive function (memory loss, cognitive difficulties); sleep 
disturbances (delayed onset, frequent awakenings)
Genitourinary tract Vulvovaginal atrophy, dyspareunia; sexual dysfunction; urgency/stress 
incontinence; urinary frequency; recurrent urinary infection; vaginal infection
Musculoskeletal system Joint/muscle pain; loss of muscle mass (sarcopenia); loss of bone mass 
(osteopenia, increased risk for fractures)
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on the presence and type of risk factors (e.g. obesity, smoking, 
hypertension, diabetes). Risk assessment tools have been 
developed for osteoporosis (e.g. FRAX®), breast cancer  
(e.g. IBIS Risk Assessment Tool), CVD (e.g. Systematic COronary 
Risk Evaluation; SCORE), and diabetes (QDiabetes®). Evaluating 
comorbidities can inform product selection and route of 
administration to minimize risk.
All candidates for MHT must be assessed for contraindications. 
MHT is contraindicated in women with known, suspected, or 
a history of breast cancer.6 Although observational evidence 
suggests that MHT does not further alter risk in women with 
a family history of breast cancer10 and, in some countries 
(e.g. Belgium and Switzerland), a family history is not a 
contraindication, it is prudent to not prescribe MHT for women 
at high risk of breast cancer. Clinical judgment is warranted 
by taking into consideration the number of cases and age 
at diagnosis within a given family history. Breast cancer risk 
calculators can also be of value.
Examination and investigations
All MHT candidates must undergo a physical examination, 
including a blood pressure check. Blood tests (e.g. fasting lipid 
profile, blood glucose level) are optional and can be selected 
based on the clinical picture that emerges during personal and 
family history taking.
In some countries (e.g. Belgium), mammography is generally 
performed before prescribing MHT. In other countries, results 
from government breast-screening programs, which are 
typically recommended every 2-3 years for women aged  
50-70 years, may be used to inform the appropriateness of 
MHT for candidate patients.
Although some countries (e.g. Germany, Switzerland) perform 
endometrial ultrasound for candidate patients, systematic 
screening of asymptomatic patients for the early detection of 
endometrial cancer is not recommended due to the number of 
false positives.41 Endometrial ultrasound is not necessary for not-
at-risk, non-obese, non-diabetic patients with regular bleeding. 
Conversely, abnormal vaginal bleeding before or during 
MHT should prompt consideration of an ultrasound to check 
endometrial thickness (cut-off <4 mm) and exclude pathologies.
A dual energy x-ray absorptiometry (DEXA) bone density scan 
is performed routinely in some countries (e.g. Belgium) but not 
in others (e.g. UK). Procedure cost and DEXA availability are 
among the factors influencing local practice habits. DEXA is not 
mandatory for women with no risk factors who are candidates 
for or already receiving MHT, although it may be indicated in 
women at risk for osteoporosis.
Special situations
All women should be characterized before starting MHT, as 
each may have personal risk factors or a relevant family history 
(e.g. CVD, VTE, breast cancer) to consider. Identifying risk 
factors assists in individualizing treatment to minimize risk.6
Age
Women who enter the menopause before the age of 40 years 
have premature ovarian insufficiency. MHT is indicated to 
provide symptom relief and lower the risk of osteoporosis (and 
CVD).42,43 The strongest evidence for endometrial protection 
is with cyclical combined treatment. Patient preference for 
route of administration of each MHT component must be 
considered when prescribing.42,43 MHT should be continued at 
least until the natural age of menopause (~51–52 years), then 
reassessed.42-44 As spontaneous ovarian activity may resume 
in women with premature ovarian insufficiency, some form of 
contraception may be required.45
Menopause between the ages of 40 and 45 years is considered 
early-onset menopause. The risk of CVD and mortality is 
higher in this group compared with women who enter 
menopause after the age of 50 years.46 MHT is indicated 
for early menopause to control symptoms and prevent 
diseases associated with estrogen deficiency. Transdermal 
or oral estrogen therapy plus cyclical progestogen is 
generally considered first-line therapy for women with early 
menopause.44
The usual age for menopausal transition is between 45 and 
55 years. Within this group, women aged 45–50 years are 
managed similarly to women aged >50 years. Women aged 
50–59 years are the main target population for MHT. Initiating 
MHT is an option for symptomatic women aged ≥60 years,10 
although careful assessment is required to confirm that 
symptoms are indeed menopausal and to identify risk factors. 
Transdermal or ultra-low dose oral formulations may be most 
appropriate for use in this patient population.10
High-density breast tissue
High-density breast tissue is associated with an increased 
risk of breast cancer.47,48 Progesterone in combination with 
estradiol appears less likely than other progestogens to 
increase mammographic density.30 Evidence suggesting that 
breast cancer risk is lower with micronized progesterone or 
dydrogesterone than with other progestogens8,26–28 supports 
their use in women with high breast density concerns. Tibolone 
has been shown to increase breast density to a lesser extent 
than estradiol/norethisterone acetate in postmenopausal 
women during 6 months of treatment.49
Endometriosis
In menopausal women with a history of endometriosis, MHT 
may reactivate residual disease or cause new lesions, although 
evidence is not sufficiently strong to deny treatment to 
women with severe menopausal symptoms.50 An initial step in 
selecting treatment may be to differentiate between women 
with active lesions and those with a history of lesions. For 
patients with current symptomatic endometriosis who require 
MHT, a continuous combined estrogen plus progestogen 
Stevenson JC, Rozenberg S, Maffei S, et al. Drugs in Context 2020; 9: 2020-10-1. DOI: 10.7573/dic.2020-10-1 7 of 12
ISSN: 1740-4398
REVIEW – Progestogens as a component of menopausal hormone therapy drugsincontext.com
regimen or tibolone is appropriate.51,52 In patients with a 
history of endometriosis, including those who have undergone 
hysterectomy, the possibility of residual endometrial tissue 
(e.g. lesions on the bowel) is frequently unknown. A pragmatic 
approach in hysterectomized women may be to begin MHT 
using estrogen (except in patients with known residual 
endometriosis or a history of deep infiltrating endometriosis) 
and, if symptoms return (e.g. abdominal pain), add a 
progestogen. Continuous combined MHT is also appropriate in 
this setting and tibolone can be considered.52
Metabolic disorders
All postmenopausal women with metabolic disorders, such 
as diabetes and dyslipidemia, should receive appropriate 
lifestyle, dietary, and pharmacological measures for the 
prevention of CVD. In women aged 50–59 years who 
require MHT for relief of menopausal symptoms, MHT has 
the potential to improve the cardiovascular risk profile 
by modifying certain metabolic parameters.8 Estrogen is 
associated with beneficial effects on blood glucose levels, 
insulin sensitivity, low-density lipoprotein-cholesterol (LDL-C) 
and HDL-C levels.53,54 As progestogen type can determine 
the differential effects of estrogen-induced changes in lipid 
and lipoprotein levels, the choice of agent is important. 
The least to greatest effect on metabolic parameters has 
been reported with dydrogesterone and medrogestone, 
progesterone, cyproterone acetate, medroxyprogesterone 
acetate, transdermal norethindrone acetate, norgestrel, and 
oral norethindrone acetate.50
Diabetes
The complete metabolic profile, including glucose and lipids, 
should be considered when selecting MHT for women with 
diabetes.53 In diabetic women at low CVD risk, oral estrogen 
may be preferred given its stronger benefit on glucose and 
lipid profiles compared with transdermal estrogen.55 In 
obese diabetic women and in those with a higher CVD risk, 
transdermal estrogen offers benefits in terms of triglyceride 
levels and coagulation factors.55 In either case, progestogens 
with neutral effects on glucose metabolism, such as micronized 
progesterone or dydrogesterone, should be used in women 
with insulin resistance or diabetes.55
Dyslipidemia
Triglyceride and HDL-C levels are important considerations 
given their greater impact on CVD risk in postmenopausal 
women compared with men.56 Dietary modifications and 
specific pharmacological therapy should be implemented as 
needed to correct dyslipidemia in postmenopausal women.
Although all estrogen preparations reduce LDL-C and increase 
HDL-C levels, a large pooled analysis showed that triglycerides 
are increased by oral estrogen (due to an increase in hepatic 
triglyceride synthesis) but are decreased by transdermal 
estradiol.54 As such, transdermal MHT may be most appropriate 
in women with hyperlipidemia and hypertriglyceridemia, 
whereas oral MHT may be more suitable in women with low 
HDL-C levels. Among progestogens commonly prescribed 
for MHT in Europe, progesterone, dydrogesterone, and 
nomegestrol acetate have neutral effects on estrogen-
induced modifications to blood lipids; norethisterone acetate 
attenuates the beneficial effect of estradiol on HDL-C but 
has favorable effects on triglyceride levels, LDL-C, and VLDL; 
and drospirenone has favorable effects.32 In a longitudinal 
analysis, metabolic parameters (lipid and glucose levels) were 
similarly improved among women treated for a least 2 years 
with transdermal estrogen with or without dydrogesterone, 
indicating no attenuation by dydrogesterone of estrogen-
induced beneficial effects.57
Obesity
The risk–benefit ratio of MHT differs in obese women (body 
mass index >30 kg/m2) due to an inherently higher risk 
of breast cancer58 and CVD.59 Dietary measures as well as 
hypertensive and diabetes control, where applicable, should 
be implemented to counteract cardiovascular risk in obese 
women. Transdermal MHT, at low doses, may be preferable 
for obese women, mainly because it does not increase the 
risk of VTE.5,6 Micronized progesterone and dydrogesterone 
are appropriate progestogens given their neutral effects on 
cardiovascular risk factors and lower associated risk of breast 
cancer.60,61 To minimize risk, women who have undergone 
gastric bypass surgery for extreme obesity should receive 
a transdermal estrogen/progestogen or transvaginal 
progesterone.
Hypertension
Hypertension is not a contraindication for MHT; however, blood 
pressure should be controlled to minimize cardiovascular risk. 
Transdermal MHT, at low doses, may be preferable in patients 
with hypertension.6
Smoking
Smoking is not a contraindication for MHT but is regarded as 
a morbidity. Cessation should be advised in postmenopausal 
women who smoke. Oral estrogen is metabolized more rapidly 
than transdermal estrogen in smokers, supporting the use of 
the transdermal route in these women.62 As smoking increases 
cardiovascular risk, low-dose transdermal estrogen and 
micronized progesterone or dydrogesterone may be preferred 
in view of their neutral effect on cardiovascular risk factors.55,63
Venous thromboembolism
Transdermal estrogen is associated with a lower risk of VTE than 
oral estrogen.64 Separately, there is evidence that VTE risk varies 
by type of progestogen. In patients with a history of deep vein 
thrombosis, saphenectomy, or those at risk of VTE, transdermal 
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estrogen plus micronized progesterone or dydrogesterone is 
recommended, as these combinations are associated with the 
lowest risk of VTE.64-66
Migraine
The association between MHT use and migraine in 
postmenopausal women is unclear. Migraine attacks may be 
improved by MHT if they appear after menopause or may be 
worsened by MHT if they improve after menopause. In view 
of the link between fluctuating estrogen levels and menstrual 
attacks of migraine, maintaining a stable estrogen environment 
using non-oral routes may be an appropriate strategy.67 
Women with a history of migraine should receive the lowest 
dose of transdermal estrogen necessary to control menopause 
symptoms.67 Continuous formulations (e.g. continuous 
combined transdermal preparations or levonorgestrel 
intrauterine system) are preferred to avoid the adverse effect 
of cyclical progestogens on migraine.67 As migraine with aura 
is a risk factor for stroke, women with a past or current history 
should receive non-oral MHT.67
Surgery
The need to discontinue MHT prior to elective surgery 
depends on the type of surgery (e.g. day surgery versus a 
more complex procedure requiring immobilization and 
prolonged hospitalization). In patients not at risk of VTE who 
will be mobilized soon after surgery, discontinuing MHT 
before surgery is likely unnecessary. In patients receiving oral 
MHT who are at high risk of VTE after surgery, a therapeutic 
window or change to transdermal MHT prior to surgery can be 
considered.
Miscellaneous conditions
Certain patients (e.g. those with autoimmune diseases) 
may react adversely to MHT or experience deterioration in 
their condition during hormone therapy. In patients with 
systemic lupus erythematosus, the risk–benefit ratio of 
MHT must be weighed carefully due to the increased risk of 
VTE, cardiovascular events, and disease flare.68 Conversely, 
as rheumatoid arthritis is a risk factor for osteoporosis, its 
presence may be an added consideration in symptomatic 
women who are candidates for MHT.
The safety of MHT in patients with a given disease, especially 
a rare disease, is not always known. With some exceptions, a 
general approach may be that premenopausal women who 
have had bilateral oophorectomy as part of the management 
plan for a given disease are not candidates for MHT. Otherwise, 
MHT may be appropriate. In women with BRCA1 or BRCA2 
mutations who have had risk‐reducing bilateral salpingo‐
oophorectomy, MHT can be used in the absence of a personal 
history of breast cancer.42
Conclusions
In suitable candidates, MHT is an important tool to treat 
menopausal symptoms and maintain bone health. 
Progestogens are added to estrogens to provide endometrial 
protection in women with a uterus. When a progestogen 
is required, micronized progesterone and dydrogesterone 
appear to be the safest options for minimizing cardiovascular, 
thromboembolic, and breast cancer risks compared with other 
progestogens. MHT, including the choice of progestogen, 
should be individualized according to the patient’s medical 
history and treatment goals.
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